Limb-Girdle Muscular Dystrophy (LGMD) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Asklepios, Myonexus, Sarepta, Atamyo

Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 20+ key pharma and biotech companies are working on 25+ pipeline drugs in the Limb-Girdle Muscular Dystrophy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Limb-Girdle Muscular Dystrophy (LGMD) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Limb-Girdle Muscular Dystrophy Market

The Limb-Girdle Muscular Dystrophy Pipeline report embraces in-depth commercial, regulatory, and Limb-Girdle Muscular Dystrophy clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Limb-Girdle Muscular Dystrophy drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Limb-Girdle Muscular Dystrophy (LGMD) Pipeline Analysis

The report provides insights into: 

The report provides detailed insights into the emerging therapies for Limb-Girdle Muscular Dystrophy treatment and the aggregate therapies developed by major pharma companies.

It accesses the different Limb-Girdle Muscular Dystrophy therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

It outlines the major Limb-Girdle Muscular Dystrophy companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

The report evaluates the Limb-Girdle Muscular Dystrophy drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Limb-Girdle Muscular Dystrophy therapeutic market.

Limb-Girdle Muscular Dystrophy (LGMD) Therapeutics Landscape

The management of limb-girdle muscular dystrophy (LGMD) is supportive; no disease-modifying treatments are available. Treatment is aimed at the specific symptoms present in each individual. Specific treatment options may include physical and occupational therapy to improve muscle strength and prevent contractures; the use of various devices (e.g., canes, braces, walkers, wheelchairs) to assist with walking (ambulation) and mobility; surgery to correct skeletal abnormalities such as scoliosis; and regular monitoring of the heart and the respiratory system for the development of such complications potentially associated with some forms of LGMD.

To improve the treatment scenario, several major pharma and biotech companies are developing therapies for Limb Girdle Muscular Dystrophy. Currently, ML Bio Solutions is leading the therapeutics market with its Limb Girdle Muscular Dystrophy drug candidates in the most advanced stage of clinical development.

Limb-Girdle Muscular Dystrophy (LGMD) Companies Actively Working in the Therapeutic Market Include:

ML Bio Solutions

Myonexus Therapeutics

Sarepta Therapeutics, Inc.


Asklepios BioPharmaceutical

Atamyo Therapeutics

aTyr Pharma

BridgeBio Pharma

Catabasis Pharmaceutical

Edgewise Therapeutics

Hansa Biopharma

Vita Therapeutics

And many others

Emerging and Marketed Limb-Girdle Muscular Dystrophy (LGMD) Drugs Covered in the Report Include:

LION-101: Asklepios BioPharmaceuticals

MYO-101, MYO-102: Myonexus Therapeutics

SRP-9005: Sarepta Therapeutics

Stryka 516s: Strykagen

ATA-100: Atamyo Therapeutics

ATYR1940: aTyr Pharma

BBP-418: ML Bio Solutions

CAT-1004: Catabasis Pharmaceutical

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Limb-Girdle Muscular Dystrophy Companies Working in the Market @


Analysis of Emerging Limb-Girdle Muscular Dystrophy Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) 

Pre-clinical and Discovery stage candidates

Discontinued and inactive candidates

Route of Administration

Limb Girdle Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as





Intravenous/ Subcutaneous





Molecule Type

Products have been categorized under various Molecule types such as


Antisense oligonucleotides


Monoclonal antibody



Recombinant protein

Small molecule

Stem Cell


Learn How the Limb-Girdle Muscular Dystrophy Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Limb-Girdle Muscular Dystrophy Treatment Patterns

4. Limb-Girdle Muscular Dystrophy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Limb-Girdle Muscular Dystrophy Late Stage Products (Phase-III)

7. Limb-Girdle Muscular Dystrophy Mid-Stage Products (Phase-II)

8. Limb-Girdle Muscular Dystrophy Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Limb-Girdle Muscular Dystrophy Discontinued Products

13. Limb-Girdle Muscular Dystrophy Product Profiles

14. Major Limb-Girdle Muscular Dystrophy Companies in the Market

15. Key Products in the Limb-Girdle Muscular Dystrophy Therapeutics Segment

16. Dormant and Discontinued Products

17. Limb-Girdle Muscular Dystrophy Unmet Needs

18. Limb-Girdle Muscular Dystrophy Future Perspectives

19. Limb-Girdle Muscular Dystrophy Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Traumatic Brain Injury Market

“Traumatic Brain Injury Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Traumatic Brain Injury market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Traumatic Brain Injury market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: